Rucaparib Monotherapy in Patients With Pancreatic Cancer and a Known Deleterious <i>BRCA</i> MutationRachna T. Shroff, Susan M. Domchek, Andrew V. Biankin et al.|JCO Precision Oncology|2018Cited by 177
RUCAPANC: An open-label, phase 2 trial of the PARP inhibitor rucaparib in patients (pts) with pancreatic cancer (PC) and a known deleterious germline or somatic <i>BRCA</i> mutation.Susan M. Domchek, Rachna T. Shroff, Andrew Hendifar et al.|Journal of Clinical Oncology|2016Cited by 27
Abstract B102: A phase 2, open-label study of the PARP inhibitor rucaparib in patients with pancreatic cancer and a known deleterious BRCA mutationSusan M. Domchek, Robert H. Vonderheide, Robert R. McWilliams et al.|Cancer Research|2015Cited by 4
A phase 2, open-label study of rucaparib in patients with pancreatic cancer and a known deleterious BRCA mutation.Susan M. Domchek, Robert H. Vonderheide, Robert R. McWilliams et al.|Journal of Clinical Oncology|2014Cited by 3